// App-Quantinova.ai

2827 : Effect Of Biologic Agents On Lipids and Cardiovascular Risk In Rheumatoid Arthritis Patients

Researchers

Presenter

  • Dimitrios A. Pappas

Principal Investigators

  • Ani John

  • Jeffrey R. Curtis

  • George W. Reed

  • Jeffrey D. Greenberg

  • Ashwini Shewade

  • Daniel H. Solomon

  • Joel M. Kremer

  • Tanya Sommers

Medical Centers

  • Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

  • Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA

  • Departments of Medicine Rheum Div and Hospital for Joint Diseases, New York Hospital for Joint Diseases, New York, NY

  • Albany Medical College and The Center for Rheumatology, Albany, NY

  • Columbia University, New York, NY

Locations

  • United States

Companies

  • Corrona, LLC

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • C reactive protein

  • High sensitivity C-reactive protein

  • Tumor necrosis factor

Drug/Treatment

  • Tocilizumab

  • Abatacept

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved